Neogenomics reported total revenue of $209 million, up 11% year over year, ahead of its expectations of approximately 10% growth. It raised full-year revenue guidance to $807 to $809 million from $802 to $806 million, and adjusted EBITDA guidance to approximately 60 million from 56 to 58 million. Warren Stone becomes chief executive officer effective January 4, 2027, succeeding Tony Zook, who becomes executive chair.
NEO · Neogenomics Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
NeoGenomics, Inc. reported that revenue for the three and nine months ended September 30, 2026 increased $21.5 million, or 11.4%, and $60.4 million, or 11.2%, respectively, versus 2025. Gross profit margin was 46.2% and 45.1%, respectively, compared with 42.8% and 43.0%.
NeoGenomics reported third-quarter 2026 revenue up 11% to $209 million. It raised full-year 2026 revenue guidance to $807 million to $809 million and expects adjusted EBITDA of approximately $60 million. Warren Stone, President and COO, will become CEO effective January 4, 2027.
NeoGenomics appointed Warren Stone CEO and a director effective January 4, 2027, while Tony Zook will become Executive Chairman. Preliminary third-quarter revenue is approximately $209 million, with NGS revenue growth of approximately 28%, and full-year revenue guidance is expected to rise.